Safety and clinical efficacy of the double switch from originator infliximab to biosimilars CT‐P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicenter cohort study

Data regarding double switching from originator infliximab (IFX) to IFX biosimilars in inflammatory bowel diseases (IBDs) are lacking. The purpose of this study was to evaluate the safety and efficacy of switching from originator IFX to CT‐P13 and subsequently to SB2 (double switch) in patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Mazza, Stefano, Piazza O. Sed, Nicole, Conforti, Francesco Simone, Fascì, Alberto, Rimondi, Alessandro, Marinoni, Beatrice, Casini, Valentina, Ricci, Chiara, Munari, Francesca, Pirola, Lorena, Invernizzi, Pietro, Girelli, Carlo, Lupinacci, Guido, Pastorelli, Luca, Cavallaro, Flaminia, Ferraris, Luca, Colucci, Alice, Amato, Arnaldo, Eugenio Tontini, Gian, Vecchi, Maurizio, Fiorino, Gionata, Caprioli, Flavio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8742653/
https://www.ncbi.nlm.nih.gov/pubmed/34523800
http://dx.doi.org/10.1111/cts.13131

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8742653/
https://www.ncbi.nlm.nih.gov/pubmed/34523800
http://dx.doi.org/10.1111/cts.13131

Ejemplares similares